Gee, if you'd write them up as protocols, they'd become standard of care and survivors would benefit. Doesn't anyone in stroke have two functioning neurons to rub together for a spark of intelligence? Since we have NO leadership in stroke you can't hand this off to someone else to accomplish
Glucagon-Like Receptor-1 Agonists and Stroke: a Systematic Review and Meta-Analysis of Cardiovascular Outcome Trials
Abstract
Background:
In
stroke survivors, approximately 15% and 60% exhibit concurrent diabetes
mellitus and overweight/obesity, respectively, necessitating heightened
secondary prevention efforts. Despite Glucagon-like receptor-1 agonists
(GLP-1 RAs) demonstrating improved outcomes for those with diabetes
mellitus or obesity, their underutilization persists among eligible
individuals. This systematic review and meta-analysis investigated the
impact of GLP-1 RAs on stroke risk. The findings aim to optimize the
implementation(Well, then write up and distribute a protocol on this. Writing this research article does nothing! Its been proven stroke hospitals don't keep up-to-date on research!) of this therapeutic strategy in stroke survivors with
diabetes mellitus or obesity.
Methods:
Following
PRISMA guidelines, we systematically reviewed MEDLINE and Scopus until
15/11/2023. Eligible studies included randomized cardiovascular outcome
trials (CVOTs) with individuals, with or without type 2 diabetes,
randomized to either GLP-1 RA or placebo. The outcomes were total
strokes, non-fatal strokes, and fatal strokes. Analyses were conducted
using RevMan 5.4.1.
Results:
Among
1,369 screened studies, 11 were eligible, encompassing 82,140
participants (34.6% women) with a cumulative follow-up of 247,596
person-years. In the GLP-1 RAs group, the stroke rate was significantly
lower compared to placebo (RR: 0.85, 95% CI: 0.77-0.93; NNT: 200),
showing no heterogeneity or interaction with administration frequency
(daily vs. weekly). Additionally, the GLP-1 RAs group exhibited a
significantly lower rate of non-fatal strokes compared to placebo (RR:
0.87, 95% CI: 0.79-0.95; NNT: 250), with no heterogeneity or interaction
based on administration frequency, route (oral vs subcutaneous), or
diabetes presence.
Conclusion:
In
this meta-analysis of 11 CVOTs with 82,140 participants, GLP-1 RAs
demonstrated a 16% relative reduction in stroke risk compared to
placebo. This finding may increase implementation of GLP-1 RAs by stroke
specialists in individuals with stroke and comorbid diabetes mellitus
or obesity.
No comments:
Post a Comment